Straits Times Index
3,090.31 +17.32 (+0.56%) S&P 500
4,594.63 +26.83 (+0.59%) Dow
36,245.50 +294.60 (+0.82%) Nasdaq
14,305.03 +78.83 (+0.55%) Bitcoin USD
39,751.23 +80.02 (+0.20%) CMC Crypto 200
802.76 +11.20 (+1.41%)
CollPlant Biotechnologies Ltd. (CLGN)
After hours:
| Previous close | 5.50 |
| Open | 5.26 |
| Bid | 4.75 x 1100 |
| Ask | 8.41 x 1100 |
| Day's range | 5.22 - 5.35 |
| 52-week range | 4.70 - 13.97 |
| Volume | |
| Avg. volume | 12,631 |
| Market cap | 60.127M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs.
- PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 29 at 10
- PR Newswire
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market.
